{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-24-000003","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2024-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.779849+00:00","generated_at":"2026-06-07T05:07:28.864201+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ImmunityBio secures up to $320M royalty and equity financing from Oberland Capital; $210M funded at close","bullets":["$200M non-dilutive royalty financing closed; additional $100M contingent on FDA approval of Anktiva for NMIBC (PDUFA Apr 23, 2024).","$10M equity private placement at $4.11/share; Oberland gets 5-year option for another $10M.","Nant Capital $505M notes extended to Dec 2025; conversion option at 75% premium to market.","Total 2023 capital raised reaches $850M; proceeds to fund commercialization and pipeline.","Royalty rate: initially 3%-7% of net sales (ex-China); capped at 195% of investment; may step down to 1.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-24-000003","json":"https://secwatch.observer/filing/0001326110-24-000003.json","markdown":"https://secwatch.observer/filing/0001326110-24-000003.md","text":"https://secwatch.observer/filing/0001326110-24-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000003/0001326110-24-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000003/ibrx-20231229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:07:28.864201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f6f43c7d6b0fd8047ecc4a64ca00042d7b0c61e","claim":"ImmunityBio, Inc. entered into Revenue Interest Purchase Agreement with Infinity SA LLC, an affiliate of Oberland Capital Management LLC, as collateral agent and administrative agent for the purchasers valued at $200.0 million (effective 2023-12-29).","evidence_excerpt":"On December 29, 2023 (the “Closing Date”), ImmunityBio, Inc. (the “Company”), entered into a Revenue Interest Purchase Agreement (the “RIPA”) with Infinity SA LLC (the “Purchaser Agent”), an affiliate of Oberland Capital Management LLC, as collateral agent and administrative agent for the purchasers party thereto (each, a “Purchaser”, and collectively, the “Purchasers”). Pursuant to the RIPA, the Purchasers acquired certain revenue interests (the “Revenue Interests”) from the Company for a gross purchase price of $200.0 million (the “First Payment”) paid at closing.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611024000003/0001326110-24-000003-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Infinity SA LLC, an affiliate of Oberland Capital Management LLC, as collateral agent and administrative agent for the purchasers"},{"label":"Value","value":"$200.0 million"},{"label":"Effective","value":"2023-12-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}